The collaboration will integrate both companies' supply chain tracking and patient access services to enable a more efficient path for the industry to develop the next-generation of commercial therapies.
Combining TrakCel's data tracking and personalised medicine orchestration software system with McKesson's existing high-touch patient platform, as well as both companies' expertise and support, will provide an end-to-end solution for the cell and gene therapy industry to manage the entire therapeutic supply chain.
McKesson and TrakCel will begin by developing an initial solution design. The combined solutions will then be offered to individual clients that would specifically benefit from this combination.
The blend of these product suites is specifically designed for the increasing number of developers approaching the commercial launch of cell and gene therapies. The integrated platform enables the scale-up of products towards market delivery.
This includes automatic scheduling of product-specific workflows across multiple supply chain partners and care team members, and validated chain-of-identity tracking to guarantee correct drug product delivery.
These capabilities ensure that the patient receives the correct, uncompromised treatment at the right time.
TrakCel is the market-leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries.
TrakCel's solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery.
The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.
TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. It aims to employ over 100 people by end of 2019, following a number of senior appointments in 2016 and 2017.
McKesson Corp., currently ranked 7th on the FORTUNE 500, is a leader in healthcare supply chain management solutions, retail pharmacy, healthcare technology, community oncology and specialty care.
McKesson partners with life sciences companies, manufacturers, providers, pharmacies, governments and other healthcare organisations to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.
United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities to improve patient care in every setting, one product, one partner, one patient at a time.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval